Updated November 2026
Medical device clinical evaluation is the process through which the manufacturer collects, appraises and analyses the clinical data needed to support a device’s safety, performance and clinical benefits.
Regulation (EU) 2017/745 (MDR) requires this process to be planned, documented and updated throughout the device’s life cycle.
This guide explains what clinical evaluation means, what information it considers, which documents describe the process and its results, and how it relates to post-market surveillance and the SSCP.

In this guide
- What is clinical evaluation?
- Which devices require clinical evaluation?
- What data and evidence does it consider?
- How does medical device clinical evaluation work?
- Clinical evaluation plan and report
- Clinical evaluation and clinical investigations
- Roles of the manufacturer and the notified body
- Updates, PMS and PMCF
- Relationship with the SSCP
What is clinical evaluation?
Clinical evaluation is a systematic and planned process involving the ongoing generation, collection, analysis and assessment of clinical data relating to a medical device.
Its main legal bases are Article 61 and Part A of Annex XIV to the MDR.
The process helps demonstrate conformity with the relevant general safety and performance requirements, taking into account undesirable side-effects and the acceptability of the benefit-risk ratio.
The conclusions must be consistent with the device’s characteristics, its intended purpose, risk management and the state of the art in medicine.
Clinical evaluation is not limited to a single study or the preparation of a report. It encompasses the activities through which clinical evidence is generated, assessed and kept up to date.
Which devices require clinical evaluation?
Clinical evaluation applies to medical devices subject to the relevant MDR requirements, including class I devices. It is therefore not limited to devices whose conformity assessment involves a notified body.
The level of clinical evidence needed depends on the device’s characteristics and its intended purpose. Risk classification is relevant, but does not alone determine which data are sufficient.
The Regulation also addresses specific situations. Article 61(10) covers cases where demonstrating conformity on the basis of clinical data is not deemed appropriate and requires adequate justification.
This provision does not constitute a general exemption from clinical evaluation for class I devices or devices considered simple.
A distinction applies to legacy devices, which continue to benefit from the transitional provisions of Article 120 of the MDR, subject to the conditions set out in the Regulation.
MDCG 2021-25 rev.1 clarifies that, during the transitional period, the clinical evaluation of legacy devices does not already have to comply with Article 61 and Annex XIV of the MDR.
The requirements of the relevant Directives and the MDR requirements applicable to those devices, including those relating to post-market surveillance, continue to apply. The quality management system should also address how compliance with the MDR requirements will be achieved during the transitional period.
MDCG 2020-6, by contrast, addresses the clinical evidence needed for MDR conformity assessment of devices previously CE marked under the Directives.
Distinguishing between requirements applicable during the transitional period and those needed for full MDR compliance is therefore important.
What data and evidence does it consider?
Clinical evaluation considers data relevant to the safety and performance of the device for its intended purpose.
Sources may include:
- clinical investigations of the device;
- relevant scientific literature;
- published clinical experience;
- data relating to a device for which equivalence has been demonstrated;
- clinical information collected through post-market surveillance and post-market clinical follow-up.
The availability of data does not automatically establish their adequacy. Their quality, relevance and ability to support conclusions about the device must also be considered.
Unfavourable results and limitations in the available evidence also form part of the evaluation.
The use of data relating to an equivalent device is subject to the conditions set out in the MDR. Equivalence involves technical, biological and clinical characteristics and cannot be inferred solely from commercial similarity or the same intended purpose.
MDCG 2020-5 provides further guidance on this subject.
How does medical device clinical evaluation work?
Medical device clinical evaluation follows the process described in Annex XIV, including planning, identifying available data, appraising their suitability, generating additional data where needed and analysing the evidence as a whole.
The starting point is the device’s intended purpose, together with the target populations, indications, intended clinical benefits and risks to be considered.
Evaluation identifies gaps in the available knowledge and helps determine whether further data are needed.
The conclusions must also take account of relevant diagnostic or therapeutic alternatives and the state of the art.
This process is linked to risk management and the information supplied by the manufacturer. Claims about the device’s performance and clinical benefits must be supported by the available evidence.
Clinical evaluation therefore contributes to demonstrating conformity with the applicable general safety and performance requirements while remaining consistent with the device’s technical documentation.
Clinical evaluation plan and report
Two documents play a central role:
- the Clinical Evaluation Plan (CEP);
- the Clinical Evaluation Report (CER).
The plan sets out the approach to the evaluation, including its scope, the requirements to be supported by clinical data, the methods and the aspects to be considered.
The report documents the results of the process, the analysis of the data and the conclusions drawn from the available clinical evidence.
Article 61(12) requires the clinical evaluation report to form part of the technical documentation referred to in Annex II, except for custom-made devices, which are subject to specific documentation requirements.
The report does not replace the underlying documents and data.
The plan and the report therefore serve different purposes: the plan establishes how the evaluation is to be conducted, while the report presents its results and conclusions.
Clinical evaluation and clinical investigations
Clinical evaluation and clinical investigation are not interchangeable terms.
The overall process of assessing the evidence is clinical evaluation. A clinical investigation is a systematic investigation involving human subjects, undertaken to assess the safety or performance of a device.
A clinical investigation may therefore generate data used in the clinical evaluation.
For implantable devices and class III devices, Article 61 establishes a general requirement to perform clinical investigations, subject to the exceptions and conditions set out in the Regulation.
MDCG 2023-7 provides guidance on the application of Article 61(4)–(6), including circumstances in which new clinical investigations may not be required.
For other devices, the need for new investigations also depends on the available evidence and the questions that remain unresolved.
The availability of scientific literature does not automatically remove the need to generate new data.
Roles of the manufacturer and the notified body
The manufacturer is responsible for planning, conducting, documenting and updating the clinical evaluation.
Where required by the applicable conformity assessment procedure, the notified body examines the clinical evaluation and the evidence supporting the manufacturer’s conclusions.
The scope and arrangements for this assessment depend on the device class and the applicable procedure.
The involvement of a notified body does not transfer responsibility for the clinical evaluation from the manufacturer to the notified body.
MDCG 2020-13 provides a template for the Clinical Evaluation Assessment Report (CEAR), in which the notified body documents its assessment of the clinical evaluation. It is not a CER template for manufacturers.
Updates, PMS and PMCF
Clinical evaluation continues after the device has been placed on the market.
Article 61(11) requires the clinical evaluation and its documentation to be updated throughout the device’s life cycle using data obtained through post-market surveillance and PMCF.
Post-market surveillance, or PMS, involves collecting and analysing information on experience gained with the device.
Post-market clinical follow-up, or PMCF, addresses clinical aspects through the proactive collection and evaluation of data from the use of the device.
New information may confirm previous conclusions or reveal risks, limitations or a need for further investigation.
For class III devices and implantable devices, Article 61(11) also requires the PMCF evaluation report and, if indicated, the SSCP to be updated at least annually with those data.
This provision does not establish a general annual update frequency for all clinical evaluation reports. The obligation to keep the clinical evaluation up to date throughout the device’s life cycle nevertheless remains.
Updating the evaluation therefore involves more than changing the date of the report: it requires considering whether the evidence and conclusions remain adequate.
Relationship with the SSCP
For devices covered by Article 32 of the MDR, the Summary of Safety and Clinical Performance, or SSCP, provides public access to selected information derived from the clinical evaluation.
SSCP includes a summary of the clinical evaluation and relevant information on PMCF.
The clinical evaluation report and the SSCP serve different purposes and audiences. The former forms part of the technical documentation under the applicable provisions; the latter presents the information required by the Regulation to the public.
SSCP does not replace the CER and must remain consistent with the updated evidence and documentation.
Further reading: Summary of Safety and Clinical Performance | SSCP.
Why this guide is not a clinical evaluation template
This page explains the purpose and general regulatory framework of clinical evaluation.
It does not provide a completed CEP or CER template or determine which evidence is sufficient for a particular device.
The content, methods and conclusions depend on the product’s characteristics, intended purpose, risks and available data.
This guide is for information only and does not establish clinical evaluation procedures for individual products.
Informational note
This guide is published for informational purposes only and does not constitute regulatory, legal, technical or professional advice.
The information is based on publicly available sources and was verified as of the date of publication or the latest update of this page. It may therefore not reflect subsequent changes or developments.
For assessments relating to specific cases, reference should be made to the official texts, the latest documentation issued by the competent authorities and, where appropriate, qualified professionals.
Official sources
- Regulation (EU) 2017/745 — EUR-Lex: in particular Articles 2, 10, 32, 61 and 120 and Annexes II and XIV. The latest consolidated version should also be consulted.
- Italian Ministry of Health — Clinical evaluation of medical devices — in Italian.
- MDCG 2020-5 — Clinical Evaluation: Equivalence.
- MDCG 2020-6 — Clinical evidence needed for medical devices previously CE marked under the Directives.
- MDCG 2021-25 rev.1 — Application of MDR requirements to legacy devices.
- MDCG 2023-7 — Guidance on exemptions from the requirement to perform clinical investigations.
Share this guide
If you find this guide useful, you can share it with other professionals interested in MDR.
Want to stay updated on MDR and IVDR?
Subscribe to MDN – Medical Device News for free.
Subscribers receive the newsletter by email every Monday, one week before publication on the website.
Related resources
- What is the MDR?
- MDR Notified Bodies
- MDR Classification Rules
- MDR Codes
- MDR Harmonised Standards
- MDR Post-Market Surveillance
- UDI and Basic UDI-DI
Copyright and reuse
© Simone Ronco. Unless otherwise stated, the editorial content of this guide is an original work.
Short excerpts may be quoted with attribution to the author and a link to the original page.
Full reproduction, translation, adaptation or commercial use of the content requires prior written permission.